Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection

Accounts of Chemical Research
F George NjorogeJohn J Piwinski

Abstract

More than 170 million people worldwide are affected by the hepatitis C virus (HCV). The disease has been described as a "silent epidemic" and "a serious global health crisis". HCV infection is a leading cause of chronic liver disease such as cirrhosis, carcinoma, or liver failure. The current pegylated interferon and ribavirin combination therapy is effective in only 50% of patients. Its moderate efficacy and apparent side effects underscore the need for safer and more effective treatments. The nonstructural NS3 protease of the virus plays a vital role in the replication of the HCV virus. The development of small molecule inhibitors of NS3 protease as antiviral agents has been intensively pursued as a viable strategy to eradicate HCV infection. However, it is a daunting task. The protease has a shallow and solvent-exposed substrate binding region, and the inhibitor binding energy is mainly derived from weak lipophilic and electrostatic interactions. Moreover, lack of a robust in vitro cell culture system and the absence of a convenient small animal model have hampered the assessment of both in vitro and in vivo efficacy of any antiviral compounds. Despite the tremendous challenges, with access to a recently developed cell-based...Continue Reading

References

Apr 20, 1967·Biochemical and Biophysical Research Communications·I Schechter, A Berger
Oct 1, 1994·Clinical Microbiology Reviews·J A Cuthbert
Jan 1, 1997·Springer Seminars in Immunopathology·C M Walker
Jun 24, 1998·Biochemistry·C SteinkühlerR De Francesco
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·M Llinàs-BrunetD Lamarre
May 21, 1999·Analytical Biochemistry·R ZhangB A Malcolm
Jul 31, 1999·Science·J Cohen
Aug 19, 1999·The New England Journal of Medicine·M J AlterH S Margolis
Feb 12, 2000·Journal of Medicinal Chemistry·D LeungD P Fairlie
Feb 24, 2001·Seminars in Liver Disease·W J Wall
Aug 2, 2001·Nature Medicine·D F MercerN M Kneteman
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Oct 31, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jay H Hoofnagle
Dec 12, 2002·Chemical Reviews·James C PowersKaren Ellis James
Oct 31, 2003·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Robert S Brown, Paul J Gaglio
Mar 10, 2005·Chemical Reviews·Joel D A TyndallDavid P Fairlie
Aug 19, 2005·Nature·Brett D Lindenbach, Charles M Rice
Aug 19, 2005·Nature·Raffaele De Francesco, Giovanni Migliaccio
Aug 19, 2005·Nature·Michael Houghton, Sergio Abrignani
Aug 19, 2005·Nature·Jordan J Feld, Jay H Hoofnagle
Jan 3, 2006·Bioorganic & Medicinal Chemistry Letters·Stéphane L BogenF George Njoroge
Feb 3, 2006·Journal of Medicinal Chemistry·Kevin X ChenViyyoor Girijavallabhan
Sep 7, 2006·Nature Reviews. Drug Discovery·Boris Turk

❮ Previous
Next ❯

Citations

Jan 12, 2013·Journal of Chemical Information and Modeling·Hajira Ahmed Hotiana, Muhammad Kamran Haider
Jun 21, 2011·Chemical Reviews·Nicholas J Turner
Jul 19, 2011·Journal of Medicinal Chemistry·Rui LiuGang Liu
Apr 22, 2011·Journal of Natural Products·Riham Salah El DineEssam Abdel-Sattar
Nov 30, 2010·Nature Chemical Biology·Margit HagelJuswinder Singh
Sep 22, 2010·Chemical Communications : Chem Comm·Anass ZnabetEelco Ruijter
Sep 12, 2012·The Journal of Biological Chemistry·Jonas KüglerJohn Collins
Feb 18, 2010·Future Virology·Craig A Belon, David N Frick
Jan 1, 2010·International Journal of Molecular Sciences·Zhiwei YangLijun Zhou
Nov 23, 2013·International Journal of Molecular Sciences·Jing LiKaixian Chen
Jan 13, 2016·Expert Opinion on Drug Discovery·Adebayo A AdeniyiMahmoud E S Soliman
Sep 4, 2008·Expert Opinion on Emerging Drugs·Erik De Clercq
Jul 23, 2013·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Warren N SchmidtRaymond T Chung
Dec 15, 2015·Metabolic Engineering·Matthew MouraKeith E J Tyo
Apr 30, 2009·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Helge MyrmelBirgitta Asjø
Jul 19, 2013·Annals of the New York Academy of Sciences·Daria J HazudaSrikanth Venkatraman
Sep 15, 2012·Clinical Therapeutics·Mei H ChangHoratio B Fung
Feb 28, 2017·Antiviral Research·Guangdi Li, Erik De Clercq
Nov 3, 2016·Chemistry : a European Journal·Anna Żądło-DobrowolskaRyszard Ostaszewski
Feb 24, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shwu-Chen TsayJohan Neyts
May 14, 2011·Antiviral Chemistry & Chemotherapy·Lynne Cregar-HernandezStephen A Margosiak
Feb 11, 2010·Angewandte Chemie·Valentin KöhlerNicholas J Turner
Dec 12, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jerika T Lam, Susan Jacob
Apr 4, 2019·Organic & Biomolecular Chemistry·Alagesan MuthukumarGovindasamy Sekar
May 2, 2012·Chemical Society Reviews·Corien de GraaffRomano V A Orru

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.